Unity Biotechnology Inc [UBX] stock prices are up 16.76% to $2.09 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The UBX shares have gain 22.22% over the last week, with a monthly amount glided 109.00%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Unity Biotechnology Inc [NASDAQ: UBX] stock has seen the most recent analyst activity on August 22, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $8. Previously, Wedbush upgraded its rating to Outperform on November 16, 2023, and elevated its price target to $4. On January 04, 2022, upgrade upgraded it’s rating to Buy. Mizuho upgraded its rating to a Buy and increased its price target to $7 on November 10, 2021. Citigroup upgraded its rating to a Buy but $6 remained the price target by the analyst firm on June 28, 2021. H.C. Wainwright started tracking with a Buy rating for this stock on June 07, 2021, and assigned it a price target of $12. In a note dated February 16, 2021, Citigroup downgraded an Sell rating on this stock and boosted its target price from $5 to $6.
The stock price of Unity Biotechnology Inc [UBX] has been fluctuating between $0.94 and $2.02 over the past year. Unity Biotechnology Inc [NASDAQ: UBX] shares were valued at $2.09 at the most recent close of the market.
Analyzing the UBX fundamentals
Gross Profit Margin for this corporation currently stands at 0.53% with Operating Profit Margin at -17.22%, Pretax Profit Margin comes in at -11.51%, and Net Profit Margin reading is -11.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -1.01 and Total Capital is -0.85. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8600 points at the first support level, and at 1.6300 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.2600, and for the 2nd resistance point, it is at 2.4300.
Ratios To Look Out For
It’s worth pointing out that Unity Biotechnology Inc [NASDAQ:UBX]’s Current Ratio is 3.45. On the other hand, the Quick Ratio is 3.45, and the Cash Ratio is 1.01.
Transactions by insiders
Recent insider trading involved Ghosh Anirvan, Chief Executive Officer, that happened on Nov 04 ’24 when 432.0 shares were sold. CFO & Head of Corp. Dev., Sullivan Lynne Marie completed a deal on Nov 04 ’24 to sell 136.0 shares. Meanwhile, Chief Legal Officer Nguyen Alexander Hieu sold 149.0 shares on Nov 04 ’24.
